Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025545 · ClinicalTrials.gov registry record · Phase 2
Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00025545 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center.
The verdict
NCT00025545, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Transplanted peripheral stem cells can sometimes be rejected by the body's tissues. Treating donor peripheral stem cells with filgrastim may increase the number of donor white blood cells. This may help to decrease the rejection of the transplanted cells in patients receiving them as treatment for acute leukemia. PURPOSE: Phase II trial to study the effectiveness of filgrastim-treated donor peripheral stem cells in treating patients with acute leukemia who are undergoing peripheral stem cell transplantation.
Interventions
- DRUG cyclophosphamide
- RADIATION radiation therapy
- DRUG methotrexate
- PROCEDURE peripheral blood stem cell transplantation
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-03 |
| Est. Completion | 2002-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00025545
The ClinicalTrials.gov registry entry for NCT00025545 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00025545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00025545 about?
NCT00025545 is a clinical study titled "Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>". RATIONALE: Transplanted peripheral stem cells can sometimes be rejected by the body's tissues. Treating donor peripheral stem cells with filgrastim may increase the number of donor white blood cells. This may help to decrease the rejection of the transplanted cells in patients receiving them as trea...
What is the current status of trial NCT00025545?
This trial is currently completed. It is a Phase 2 study. The study started on 1996-03. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00025545?
The interventions under investigation include: cyclophosphamide (DRUG), radiation therapy (RADIATION), methotrexate (DRUG), peripheral blood stem cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00025545?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.